Literature DB >> 6688910

Changes in bone metabolism during treatment of acromegaly.

J W Bijlsma, J W Nortier, S A Duursma, R J Croughs, R Bosch, J H Thijssen.   

Abstract

Bone metabolism was studied in 17 acromegalic patients, who responded to either medical treatment with bromocriptine (12 patients), or to transsphenoidal surgery (5 patients). Parameters of bone turnover decreased, e.g. serum acid phosphatase (9.2 +/- 0.7 vs 8.1 +/- 0.6 U/l, P less than 0.05) and the ratio of hydroxyproline/creatinine (33.6 +/- 4.4 vs 18.3 +/- 2.0, P less than 0.01) in the urine. No changes were observed in parathyroid function or concentrations of calcitonin. Serum 1,25-dihydroxycholecalciferol decreased (32.6 +/- 3.6 vs 20.6 +/- 1.8 ng/l, P less than 0.01) and 24,25-dihydroxycholecalciferol increased (4.3 +/- 0.6 vs 6.7 +/- 1.0 micrograms/l, P less than 0.05). No correlation between the percentual changes in serum growth hormone levels and 1,25-dihydroxycholecalciferol was found, suggesting an indirect effect of growth hormone on the renal 25-hydroxycholecalciferol-1-alpha-hydroxylase. The possible mechanisms involved are discussed, including the effects of growth hormone and somatomedin on bone.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6688910     DOI: 10.1530/acta.0.1040153

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  3 in total

Review 1.  Acromegaly update--etiology, diagnosis and management.

Authors:  S Melmed; J A Fagin
Journal:  West J Med       Date:  1987-03

Review 2.  Acromegaly and non-parathyroid hormone-dependent hypercalcemia: a case report and literature review.

Authors:  Shaomin Shi; Lan Zhang; Yerong Yu; Chun Wang; Jianwei Li
Journal:  BMC Endocr Disord       Date:  2021-05-01       Impact factor: 3.263

3.  Association of clinical and laboratory parameters with ambulatory arterial stiffness index in acromegaly patients.

Authors:  Faruk Kilinc; Zafer Pekkolay; Fatih Demircan; Nevzat Gozel; Alpaslan Kemal Tuzcu
Journal:  Pak J Med Sci       Date:  2018 Jan-Feb       Impact factor: 1.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.